Ramsay Healthcare Limited (ASX: RHC), operating in 6 countries with a network of close to 225 hospitals and ranked among the top 5 private hospital operators in the world, announced full year FY16 results ending June 30th 2016.
Group revenue surged to $8.7 billion from $7.35 billion, an increase of 18.1 percent from the previous year while the EBIT was up 11.6 percent to $897.1 million during the same period. Core NPAT was at $481.4 million, a robust increase of 16.8 percent from the previous year.
The Managing Director of Ramsay Health Care Christopher Rex said the Company delivered outstanding results as all verticals performed at or above expectations. He attributed the strong financial performance to excellent growth in volumes, ongoing efficiencies, strategic acquisitions and additional investment in the existing facilities.
- EBITDA rose by a solid 14.7 percent to $1.27 billion from $1.1 billion in 2015
- Core EPS derived from Core NP increased to 231.4 cents from 196.6 cents
- Completed integration of Ramsay Sante and Generale de Sante
- Completed capacity expansions leading to an increase of 500 beds and 26 operating theatres
- Announced a final dividend of 72 cents with the full year dividend at 119 cents, fully
According to Rex, the company has a robust balance sheet and strong cash flow generation which gives the flexibility to fund increasing demand for to expand brownfield capacity, acquisitions in the futures and ongoing working capital requirements. He considers all regions to be experiencing ageing and growing populations and with the emergence of medical innovation and therapies to check proliferation of chronic diseases, he expects the demand for healthcare to rise considerably.
The company is expecting core NPAT to increase by 10 percent and core EPS to surge by 12 percent in FY17, a modest increase compared to FY16.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd currently hold positions in: BHP, BKY, KCN, PDN, and RIO. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.